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Introduction
Central precocious puberty (CPP) presenting at a very
young age is likely to have an underlying pathology.
One of the pathologies is hypothalamic hamartoma
(HH), a non-neoplastic tumour-like lesion located at the
floor of the third ventricle, near the tuber cinereum.
Two young children with CPP due to HH without gelas-
tic seizures or mental retardation were successfully man-
aged and described in this report.
Cases
Case 1
An 18-months-old girl presented with vaginal bleeding.
Physical examination showed breast Tanner stage (TS) 4
with pubic hair TS2. Her follicle-stimulating hormone
(FSH), luteinizing hormone (LH) and estradiol were in
pubertal range (6 IU/L, 8.9 IU/L, 281 pmol/L respec-
tively) with an advanced bone age of 7 years 10 months.
Brain magnetic resonance imaging (MRI) showed a
round, non-enhancing, isointense lesion at the tuber
cinereum just anterior to the mamillary body represent-
ing hypothalamic hamartoma. She responded well with
intramuscular GnRH analogue with resolution of preco-
cious puberty. She is currently 9 years, remains prepu-
bertal with maintenance dose of GnRH analogue at
4.2 mcg/kg/day.
Case 2
A 20-months-old boy presented with rapid growth. Puber-
tal staging showed gonads TS2 (testicular volumes of
8 mls bilaterally) with pubic hair TS2. His FSH, LH and
testosterone were elevated (12 IU/L, 16.5 IU/L and
12.5 nmol/L respectively) with an advanced bone age (BA
3 years). His MRI brain confirmed hypothalamic hamar-
toma. GnRH analogue at conventional dose failed to
correct the excessive growth and stop the progression of
pubertal development until a higher dose at 18.5 mcg/kg/
day was given. He is currently 41/2 years and remains
prepubertal.
Conclusion
CPP secondary to hypothalamic hamartoma usually pre-
sents early, before the age of two years. Medical therapy
with GnRH analogue is still the first choice of treatment.
The dosage of GnRH varied and in patients whom stan-
dard dose showed insufficient effects, high dose is recom-
mended. Surgical intervention is reserved only for those
who failed medical therapy or for those with intractable
seizures.
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